Alzheimer's disease
Conditions
Interventions
Huanshaodan group:Oral rejuvenating pills
Control group:None
Acupuncture and moxibustion Therapy of Flying Eight Methods:Acupuncture and moxibustion Therapy of Flying Eight Methods
Acupuncture and moxibustion Therapy of Flying Eight Methods combined with HuanshaDan:Acupuncture and moxibustion Therapy of Flying Eight Methods combined with HuanshaDan
Sponsors
Chengdu Eighth People's Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 95 Years
Inclusion criteria
Inclusion criteria: ? Age = 60 years old; ? Conforming to the diagnostic criteria for mild to moderate spleen kidney deficiency type of AD: Referring to the core clinical standards for AD dementia developed by the National Institute of Aging (NIA) and the Alzheimer's Association (AA) in the United States, the diagnosis is highly likely to be AD; Progressive memory or other cognitive impairment for = 3 months; MMSE score of the Simplified Mental State Scale: Illiteracy = 19 points; Primary school = 22 points, secondary school and above = 24 points; Clinical dementia rating (CDR) score = 1 point; Daily living ability ADL (14 items) score = 17 points; Using the Dementia Syndrome Classification Scale (SDSD) to screen AD patients with spleen and kidney deficiency; ? Willing to accept and cooperate with the implementation of this study; ? The expected check-in time is no less than three months.
Exclusion criteria
Exclusion criteria: ? Cognitive impairment caused by intracranial lesions, or other neurological diseases (such as Parkinson's, stroke, epilepsy, etc.); ? Currently undergoing other cognitive therapy; ? Suffering from chronic diseases that hinder exercise; ? Individuals with severe cardiovascular, cerebrovascular, digestive, blood, liver and kidney dysfunction, as well as serious complications; ? Individuals with visual and auditory impairments and communication difficulties; ? Other research participants who are participating in the study that affect the results of this study; ? Patients with severe sleep disorders, anxiety, depression, and other neurological disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mini-mental State Examination;Montreal Cognitive Assessment;Hospital Anxiety and Depression Scale;PSQI; | — |
Secondary
| Measure | Time frame |
|---|---|
| NFL;GFAP;P-tau217;TNF-a;IL-6;BDNF;Aß1-40;Aß1-42; | — |
Countries
China
Contacts
Public ContactMaoquan Li; Yuzhe Fei
Chengdu Medical College; Chengdu Eighth People's Hospital
Outcome results
None listed